Bruker Quarterly Cash Flow Statement
NASDAQ: BRKRIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bruker free cash flow
In the quarter ended Jun 30, 2026, Bruker generated -$77.4 million of operating cash flow and spent $28.8 million on capital expenditures. That left free cash flow of -$106.2 million, a free-cash-flow margin of -12.7% of revenue. Bruker returned $7.5 million to shareholders through dividends.
Summary generated from market data by MetaCap's automated system. Methodology
Bruker cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -50.90M | 15.70M | 29.20M | -58.50M | 4.20M | 16.80M | 13.90M | 40.30M | 7.60M | 52.00M | 204.60M | 88.70M |
| Net Income growth (YoY) | -1311.90% | -6.55% | +110.07% | -245.16% | -44.74% | -67.69% | -93.21% | -54.57% | -86.85% | -32.82% | +108.14% | +0.34% |
| Depreciation & Amortization | 58.00M | 58.30M | 58.10M | 55.70M | 56.10M | 50.40M | 52.90M | 51.00M | 45.10M | 34.70M | 37.30M | 26.60M |
| Stock-Based Compensation | 5.60M | 6.00M | 6.30M | 6.00M | 5.70M | 5.60M | 6.80M | 6.30M | 6.90M | 5.30M | 13.10M | 5.70M |
| Change in Working Capital | -114.90M | -36.00M | — | -56.90M | -90.80M | 9.30M | -19.50M | -60.40M | -35.60M | -63.40M | 38.70M | -75.90M |
| Operating Cash Flow | -77.40M | 71.20M | 229.80M | -33.20M | -127.50M | 65.00M | 190.00M | 38.40M | 1.10M | 21.80M | 205.50M | 44.10M |
| Capital Expenditures | -28.80M | -24.20M | -22.60M | -20.90M | -21.30M | -26.00M | -36.70M | -32.60M | -24.60M | -21.40M | -31.50M | -26.90M |
| Investing Cash Flow | -25.30M | -39.70M | -55.50M | -23.80M | -91.10M | -26.10M | -60.60M | -67.60M | -1.32B | -304.20M | -36.80M | -155.00M |
| Dividends Paid | -7.50M | -7.60M | -7.50M | 0 | -7.60M | -7.70M | -7.60M | -7.60M | -7.70M | -7.30M | -7.30M | -7.40M |
| Share Repurchases | — | 0 | 0 | 0 | 0 | -10.00M | 0 | 0 | 0 | 0 | -50.40M | -79.50M |
| Debt Issued | 0 | 0 | 600.00K | 0 | 0 | 2.90M | 1.20M | 166.80M | 805.70M | 0 | -1.20M | 400.00K |
| Debt Repaid | -2.30M | -181.30M | -145.20M | -299.00M | -14.60M | -7.70M | -7.60M | -9.80M | -10.80M | -107.20M | — | — |
| Financing Cash Flow | 149.20M | -204.90M | -167.60M | 258.40M | 95.50M | -51.20M | -75.00M | -2.70M | 1.16B | 151.70M | -59.90M | -92.50M |
| Net Change in Cash | 51.50M | -165.50M | 5.80M | 201.10M | -91.50M | 1.00M | 35.00M | -21.50M | -170.10M | -148.30M | 124.70M | -211.30M |
| Free Cash Flow | -106.20M | 47.00M | 207.20M | -54.10M | -148.80M | 39.00M | 153.30M | 5.80M | -23.50M | 400.00K | 174.00M | 17.20M |
This table shows 12 quarterly periods of Bruker's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BRKR's reporting calendar. What is a cash flow statement?